Merchant Group

Any information herewith is NOT ADVICE and Merchant entities may have holdings or have earned fees in companies mentioned.

[Stevie L @LorkeStevie]

"As of February 3, 2025, 39 states have legalized cannabis for medical use and 24 states have legalized it for recreational use." @RobertKennedyJr @IngrahamAngle

[Merchant Group @merchantgrp]

Some doctors say medical marijuana can help seniors manage pain | https://t.co/0KAzEpsfmn

[Merchant Group @merchantgrp]

@chrisjamesACE @ausstockchick @realMDubbya

[Neurotech International @NeurotechInt]

📺 @7NewsAustralia has covered our NTI164 trial for Rett Syndrome, highlighting the potential of this treatment to improve key areas such as communication, anxiety, and socialisation. At @NeurotechInt, we remain committed to advancing treatment options for #paediatric neurological disorders.

Watch the full story here: https://t.co/URTjDYbsl6

#Neurotech $NTI #RettSyndrome #NTI164 #ClinicalTrials #Biotech #HopeForRett #ASX #BREAKINGNEWS #7NEWS

[Merchant Group @merchantgrp]

https://t.co/RncXDoLrcg

[Merchant Group @merchantgrp]

https://t.co/P6YX5W3NFI

[Business of Cannabis | Europe @BofC_Europe]

From Oct' 17, the majority of doctors in Germany will be able to prescribe medical cannabis for reimbursement without securing prior approval of the health insurance companies. Under the new regulations, this ratio could change significantly once again.

https://t.co/15gQU3ctmN

[jungle.java @junglejava1]

EXCLUSIVE: @GerberKawasaki Sees 'Tsunami Of Money' Pouring Into Cannabis Companies Upon Federal Legalization, Says Cannabis Is One Of 'Biggest' Opportunities Beyond AI

$GK $MSOS

https://t.co/5plleK28DH via @Benzinga

[Merchant Group @merchantgrp]

@CraigKellyPHON @NeurotechInt

[Craig Kelly:🇦🇺Foundation for Economic Education @craigkellyAFEE]

Yessssssssss !!
😀👍🔥💪🎇🎇🎇

[Merchant Group @merchantgrp]

@JessicaDAmir I’m not an expert - but whenever you think something will happen in the market based on history, you are generally disappointed…

[Neurotech International @NeurotechInt]

MST Financial has initiated research coverage on @NeurotechInt, assigning a valuation of $0.60. The MST Healthcare team, led by the highly regarded Senior Analyst Andrew Goodsall and Roy Taouk, highlights the company's current discount compared to its peers at a similar stage of development. The report also emphasises the market opportunities for NTI164 across our four clinical indications: #autism, #PANDAS/#PANS, #RettSyndrome, and cerebral palsy.

Read the full $NTI Report here: https://t.co/DrINhtdOpV
#ASXnews

[Todd Harrison @todd_harrison]

Will Cannabis be the new Ibuprofen?

#Germany 🇩🇪 #Cannabis 🌿

https://t.co/qusDQBP4gE

[Racura Oncology @RacuraOncology]

$RAC is pleased to share that @mst_financial has increased our valuation from A$2.56 to A$3.22 per undiluted share, following recent milestones. For more detailed analysis, access the full report via this link: https://t.co/f27Gv2ghdc

#BiotechInvestment

[Arovella Therapeutics ASX: ALA @WeAreArovella]

We are pleased with the research desk note prepared by @Spark_Plus describing our current product pipeline and ambitions to tackle a range of blood cancers and solid tumours. #CellTherapy

Spark Plus desk note: https://t.co/qcDW91tTgY

Product pipeline: https://t.co/z2z8naZSie

[Racura Oncology @RacuraOncology]

$RAC Race Oncology at 12-month high on promising preclinical results for drug combination in multiple myeloma treatment https://t.co/VtANfR0BQC @RaceOncology $RAONF #RAC #RAONF

[Merchant Group @merchantgrp]

https://t.co/lxds2hN1JN

Good article about German market at the moment

[Neurotech International @NeurotechInt]

In a recent #investor webinar, our Executive Director, Dr Thomas Duthy, shared exciting updates on our progress in developing a treatment for #RettSyndrome.

Dr Duthy highlighted the success of our Phase I/II clinical trial (NTIRTT1) using NTI164, a broad-spectrum cannabinoid drug therapy. The trial demonstrated significant clinical benefits and safety in girls with Rett Syndrome.

Dr. Duthy expressed his pride in $NTI's achievements, stating, "The company has delivered in spades. We have had three clinical trials in #PANDAS, #PANS, #Autism and now Retts Syndrome. All basically deliver results and we're very proud of that."

#ClinicalTrial #Neuroscience #biotech #smallcaps #smallcapstocks #biotechnology

[Neurotech International @NeurotechInt]

We've received positive results from our Phase I/II clinical trial, NTIRTT1, investigating NTI164, a cannabinoid drug therapy, for Rett Syndrome. The trial, involving 14 female pediatric patients, showed statistically significant clinical improvement with #NTI164 compared to baseline. The primary endpoint, Clinical Global Impression – Improvement (CGI-I) at 12 weeks, was met with a mean improvement of -0.3 (p=0.04), indicating a favorable comparison to the FDA-approved Rett Syndrome drug, DAYBUE™ (trofinetide). All patients completed the 12-week treatment, and data collection is ongoing for further analysis on safety and secondary endpoints.

NTI164 has shown promise in other neurological disorders in children like #autism and #PANDAS/PANS. #RettSyndrome, a rare genetic disorder primarily affecting girls, has limited treatment options, making these results significant for potential therapeutic advancements.

Read the full $NTI #ASX Announcement here: https://t.co/p8QkmEuWxr

#Neurotech #RettSyndromeTrial #CannabinoidTherapy #PediatricNeurology #ClinicalTrialResults #RareDiseaseTreatment #NeurologicalDisorders #MECP2Mutation #DrugDevelopment #HealthcareInnovation #asxnews

[Javier Hasse @JavierHasse]

Canopy Growth CEO Says German Cannabis Market Has 'Ability To Grow 10x' Following Legalization $CGC https://t.co/zUXoKUKP0m via @Benzinga @CanopyGrowth